The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Showing 8 / 1308 articles
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
The landscape of medical weight loss has been revolutionized by potent peptide therapies. Among the most talked-about are semaglutide and tirzepatide, the active ingredients in popular medications like Wegovy, Ozempic, Zepbound, and Mounjaro. But when it comes to shedding pounds, which one truly takes the lead? This article delves into the science, the studies, and the practical differences to help you understand their comparative effectiveness.
As GLP-1 medications become more accessible, older adults are asking: 'Am I too old?' This guide explores the nuances of using these powerful drugs for weight loss in seniors, emphasizing health over age.
Discover the single most important question to ask before starting GLP-1 medications like Ozempic or Wegovy. Learn how to ensure sustainable weight loss and avoid the common pitfalls of viewing these drugs as a magic cure.
Peptide therapy is rapidly gaining traction far beyond the well-known GLP-1 medications. This deep dive explores the science, the 'health-maxing' movement, supply chain complexities, and the crucial regulatory landscape shaping the future of these powerful compounds.
